Colorectal cancer classification and cell heterogeneity: A systems oncology approach

International Journal of Molecular Sciences

Volumn 16, Issue 6, 2015, Pages 13610-13632

  Blanco Calvo, Moisés ^a   Concha, Ángel ^a   Figueroa, Angélica ^a   Garrido, Federico ^b,c,d   Valladares Ayerbes, Manuel ^a  

^a HOSPITAL JUAN CANALEJO   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^d Instituto Biosanitario de Granada ibs GRANADA   (Spain)

Author keywords

Cancer systems biology; Classification; Colorectal cancer; Heterogeneity; Molecular pathology; Precision medicine; Targeted therapy

Indexed keywords

B RAF KINASE; BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN; OXALIPLATIN; PANITUMUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN MLH1; RAS PROTEIN; WNT PROTEIN;

CANCER CLASSIFICATION; CELL HETEROGENEITY; CHROMOSOMAL INSTABILITY; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; CPG ISLAND; DRUG TARGETING; EPITHELIAL MESENCHYMAL TRANSITION; GENE; GENE MUTATION; GENETIC VARIABILITY; GENOMIC INSTABILITY; HUMAN; KRAS GENE; METASTASIS; MICROSATELLITE INSTABILITY; MOLECULAR PATHOLOGY; NRAS GENE; REVIEW; ANIMAL; CARCINOGENESIS; CLASSIFICATION; CLONAL EVOLUTION; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETIC HETEROGENEITY; GENETICS; METABOLISM; PATHOLOGY; SYSTEMS BIOLOGY;

ANIMALS; CARCINOGENESIS; CLONAL EVOLUTION; COLORECTAL NEOPLASMS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC HETEROGENEITY; HUMANS; SYSTEMS BIOLOGY;

EID: 84934978026     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms160613610     Document Type: Review

References (119)

1. Aparicio, S.; Caldas, C. The implications of clonal genome evolution for cancer medicine. N. Engl. J. Med. 2013, 368, 842–851.
2. Marusyk, A.; Almendro, V.; Polyak, K. Intra-tumour heterogeneity: A looking glass for cancer? Nat. Rev. Cancer 2012, 12, 323–334.
3. Swanton, C. Intratumor heterogeneity: Evolution through space and time. Cancer Res. 2012, 72, 4875–4882.
4. Burrell, R.A.; McGranahan, N.; Bartek, J.; Swanton, C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013, 501, 338–345.
5. Dienstmann, R.; Salazar, R.; Tabernero, J. The evolution of our molecular understanding of colorectal cancer: What we are doing now, what the future holds, and how tumor profiling is just the beginning. Am. Soc. Clin. Oncol. Educ. Book 2014, 34, 91–99.
6. Colussi, D.; Brandi, G.; Bazzoli, F.; Ricciardiello, L. Molecular pathways involved in colorectal cancer: Implications for disease behavior and prevention. Int. J. Mol. Sci. 2013, 14, 16365–16385.
7. Goel, A.; Arnold, C.N.; Niedzwiecki, D.; Chang, D.K.; Ricciardiello, L.; Carethers, J.M.; Dowell, J.M.; Wasserman, L.; Compton, C.; Mayer, R.J., et al. Characterization of sporadic colon cancer by patterns of genomic instability. Cancer Res. 2003, 63, 1608–1614.
8. Markowitz, S.D.; Bertagnolli, M.M. Molecular origins of cancer: Molecular basis of colorectal cancer. N. Engl. J. Med. 2009, 361, 2449–2460.
9. Sinicrope, F.A.; Sargent, D.J. Molecular pathways: Microsatellite instability in colorectal cancer: Prognostic, predictive, and therapeutic implications. Clin. Cancer Res. 2012, 18, 1506–1512.
10. Toyota, M.; Ahuja, N.; Ohe-Toyota, M.; Herman, J.G.; Baylin, S.B.; Issa, J.P. CpG island methylator phenotype in colorectal cancer. Proc. Natl. Acad. Sci. USA 1999, 96, 8681–8686.
11. Wood, L.D.; Parsons, D.W.; Jones, S.; Lin, J.; Sjöblom, T.; Leary, R.J.; Shen, D.; Boca, S.M.; Barber, T.; Ptak, J., et al. The genomic landscapes of human breast and colorectal cancers. Science 2007, 318, 1108–1113.
12. Seshagiri, S.; Stawiski, E.W.; Durinck, S.; Modrusan, Z.; Storm, E.E.; Conboy, C.B.; Chaudhuri, S.; Guan, Y.; Janakiraman, V.; Jaiswal, B.S., et al. Recurrent R-spondin fusions in colon cancer. Nature 2012, 488, 660–664.
13. Alexandrov, L.B.; Nik-Zainal, S.; Wedge, D.C.; Aparicio, S.A.J.R.; Behjati, S.; Biankin, A.V; Bignell, G.R.; Bolli, N.; Borg, A.; Børresen-Dale, A.-L., et al. Signatures of mutational processes in human cancer. Nature 2013, 500, 415–421.
14. Xie, T.; d’ Ario, G.; Lamb, J.R.; Martin, E.; Wang, K.; Tejpar, S.; Delorenzi, M.; Bosman, F.T.; Roth, A.D.; Yan, P., et al. A comprehensive characterization of genome-wide copy number aberrations in colorectal cancer reveals novel oncogenes and patterns of alterations. PLoS ONE 2012, 7, 1–9.
15. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487, 330–337.
16. Lao, V.V.; Grady, W.M. Epigenetics and colorectal cancer. Nat. Rev. Gastroenterol. Hepatol. 2011, 8, 686–700.
17. Bardhan, K.; Liu, K. Epigenetics and colorectal cancer pathogenesis. Cancers 2013, 5, 676–713.
18. Barrow, T.M.; Michels, K.B. Epigenetic epidemiology of cancer. Biochem. Biophys. Res. Commun. 2014, 455, 70–83.
19. Ogino, S.; Lochhead, P.; Chan, A.T.; Nishihara, R.; Cho, E.; Wolpin, B.M.; Meyerhardt, J.A; Meissner, A.; Schernhammer, E.S.; Fuchs, C.S., et al. Molecular pathological epidemiology of epigenetics: Emerging integrative science to analyze environment, host, and disease. Mod. Pathol. 2013, 26, 465–484.
20. Vermeulen, L.; de Sousa E.; Melo, F.; van der Heijden, M.; Cameron, K.; de Jong, J.H.; Borovski, T.; Tuynman, J.B.; Todaro, M.; Merz, C.; Rodermond, H., et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat. Cell Biol. 2010, 12, 468–476.
21. Herrera, M.; Islam, A.B.M.M.K.; Herrera, A.; Martín, P.; García, V.; Silva, J.; Garcia, J.M.; Salas, C.; Casal, I.; de Herreros, A.G., et al. Functional heterogeneity of cancer-associated fibroblasts from human colon tumors shows specific prognostic gene expression signature. Clin. Cancer Res. 2013, 19, 5914–5926.
22. Berdiel-Acer, M.; Sanz-Pamplona, R.; Calon, A.; Cuadras, D.; Berenguer, A.; Sanjuan, X.; Paules, M.J.; Salazar, R.; Moreno, V.; Batlle, E., et al. Differences between CAFs and their paired NCF from adjacent colonic mucosa reveal functional heterogeneity of CAFs, providing prognostic information. Mol. Oncol. 2014, 8, 1290–1305.
23. Murphy, N.; Norat, T.; Ferrari, P.; Jenab, M.; Bueno-de-Mesquita, B.; Skeie, G.; Dahm, C.C.; Overvad, K.; Olsen, A.; Tjønneland, A., et al. Dietary fibre intake and risks of cancers of the colon and rectum in the European prospective investigation into cancer and nutrition (EPIC). PLoS ONE 2012, 7, doi:10.1371/journal.pone.0039361.
24. Jenab, M.; Bueno-de-Mesquita, H.B.; Ferrari, P.; van Duijnhoven, F.J.B.; Norat, T.; Pischon, T.; Jansen, E.H.J.M.; Slimani, N.; Byrnes, G.; Rinaldi, S., et al. Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations: A nested case-control study. BMJ 2010, 340, b5500, doi:10.1136/bmj.b5500.
25. Van Duijnhoven, F.J.B.; Bueno-De-Mesquita, H.B.; Calligaro, M.; Jenab, M.; Pischon, T.; Jansen, E.H.J.M.; Frohlich, J.; Ayyobi, A.; Overvad, K.; Toft-Petersen, A.P., et al. Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition. Gut 2011, 60, 1094–1102.
26. Aleksandrova, K.; Pischon, T.; Buijsse, B.; May, A.M.; Peeters, P.H.; Bueno-de-Mesquita, H.B.; Jenab, M.; Fedirko, V.; Dahm, C.C.; Siersema, P.D., et al. Adult weight change and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition. Eur. J. Cancer 2013, 49, 3526–3536.
27. Schmid, D.; Leitzmann, M.F. Television viewing and time spent sedentary in relation to cancer risk: A meta-analysis. J. Natl. Cancer Inst. 2014, 106, 1–19.
28. Ogino, S.; Fuchs, C.S.; Giovannucci, E. How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev. Mol. Diagn. 2012, 12, 621–628.
29. Lascorz, J.; Chen, B.; Hemminki, K.; Försti, A. Consensus pathways implicated in prognosis of colorectal cancer identified through systematic enrichment analysis of gene expression profiling studies. PLoS ONE 2011, 6, e18867.
30. Popovici, V.; Budinska, E.; Tejpar, S.; Weinrich, S.; Estrella, H.; Hodgson, G.; van Cutsem, E.; Xie, T.; Bosman, F.T.; Roth, A.D., et al. Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer. J. Clin. Oncol. 2012, 30, 1288–1295.
31. Donehower, L.A.; Creighton, C.J.; Schultz, N.; Shinbrot, E.; Chang, K.; Gunaratne, P.H.; Muzny, D.; Sander, C.; Hamilton, S.R.; Gibbs, R.A, et al. MLH1-silenced and non-silenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes. J. Pathol. 2013, 229, 99–110.
32. Timmermann, B.; Kerick, M.; Roehr, C.; Fischer, A.; Isau, M.; Boerno, S.T.; Wunderlich, A.; Barmeyer, C.; Seemann, P.; Koenig, J., et al. Somatic mutation profiles of MSI and MSS colorectal cancer identified by whole exome next generation sequencing and bioinformatics analysis. PLoS ONE 2010, 5, e15661.
33. Oh, S.C.; Park, Y.-Y.; Park, E.S.; Lim, J.Y.; Kim, S.M.; Kim, S.-B.; Kim, J.; Kim, S.C.; Chu, I.-S.; Smith, J.J., et al. Prognostic gene expression signature associated with two molecularly distinct subtypes of colorectal cancer. Gut 2012, 61, 1291–1298.
34. Chan, S.K.; Griffith, O.L.; Tai, I.T.; Jones, S.J.M. Meta-analysis of colorectal cancer gene expression profiling studies identifies consistently reported candidate biomarkers. Cancer Epidemiol. Biomark. Prev. 2008, 17, 543–552.
35. Marisa, L.; de Reyniès, A.; Duval, A.; Selves, J.; Gaub, M.P.; Vescovo, L.; Etienne-Grimaldi, M.-C.; Schiappa, R.; Guenot, D.; Ayadi, M., et al. Gene expression classification of colon cancer into molecular subtypes: Characterization, validation, and prognostic value. PLoS Med. 2013, 10, e1001453.
36. Schlicker, A.; Beran, G.; Chresta, C.M.; McWalter, G.; Pritchard, A.; Weston, S.; Runswick, S.; Davenport, S.; Heathcote, K.; Castro, D.A., et al. Subtypes of primary colorectal tumors correlate with response to targeted treatment in colorectal cell lines. BMC Med. Genomics 2012, 5, 66.
37. Perez-Villamil, B.; Romera-Lopez, A.; Hernandez-Prieto, S.; Lopez-Campos, G.; Calles, A.; Lopez-Asenjo, J.-A.; Sanz-Ortega, J.; Fernandez-Perez, C.; Sastre, J.; Alfonso, R., et al. Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior. BMC Cancer 2012, 12, 260.
38. Budinska, E.; Popovici, V.; Tejpar, S.; D’Ario, G.; Lapique, N.; Sikora, K.O.; di Narzo, A.F.; Yan, P.; Graeme Hodgson, J.; Weinrich, S., et al. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J. Pathol. 2013, 231, 63–76.
39. Roepman, P.; Schlicker, A.; Tabernero, J.; Majewski, I.; Tian, S.; Moreno, V.; Snel, M.H.; Chresta, C.M.; Rosenberg, R.; Nitsche, U., et al. Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. Int. J. Cancer 2013, 134, 552–562.
40. Salazar, R.; Roepman, P.; Capella, G.; Moreno, V.; Simon, I.; Dreezen, C.; Lopez-Doriga, A.; Santos, C.; Marijnen, C.; Westerga, J., et al. Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J. Clin. Oncol. 2011, 29, 17–24.
41. Venook, A.P.; Niedzwiecki, D.; Lopatin, M.; Ye, X.; Lee, M.; Friedman, P.N.; Frankel, W.; Clark-Langone, K.; Millward, C.; Shak, S., et al. Biologic determinants of tumor recurrence in stage II colon cancer: Validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581. J. Clin. Oncol. 2013, 31, 1775–1781.
42. De Sousa E., Melo, F.; Wang, X.; Jansen, M.; Fessler, E.; Trinh, A.; de Rooij, L.P.M.H.; de Jong, J.H.; de Boer, O.J.; van Leersum, R.; Bijlsma, M.F., et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat. Med. 2013, 19, 614–618.
43. Sadanandam, A.; Lyssiotis, C.A; Homicsko, K.; Collisson, E.A; Gibb, W.J.; Wullschleger, S.; Ostos, L.C.G.; Lannon, W.A; Grotzinger, C.; del Rio, M., et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat. Med. 2013, 19, 619–625.
44. Dienstmann, R.; Guinney, J.; Delorenzi, M.; de Reynies, A.; Roepman, P.; Sadanandam, A.; Vermeulen, L.; Schlicker, A.; Missiaglia, E.; Soneson, C., et al. Colorectal Cancer Subtyping Consortium Colorectal cancer subtyping consortium (CRCSC) identification of a consensus of molecular subtypes. J. Clin. Oncol. 2014, 32, 3511.
45. Dalerba, P.; Kalisky, T.; Sahoo, D.; Rajendran, P.S.; Rothenberg, M.E.; Leyrat, A.A.; Sim, S.; Okamoto, J.; Johnston, D.M.; Qian, D., et al. Single-cell dissection of transcriptional heterogeneity in human colon tumors. Nat. Biotechnol. 2011, 29, 1120–1127.
46. Meacham, C.E.; Morrison, S.J. Tumour heterogeneity and cancer cell plasticity. Nature 2013, 501, 328–337.
47. Lee, M.-C.W.; Lopez-Diaz, F.J.; Khan, S.Y.; Tariq, M.A.; Dayn, Y.; Vaske, C.J.; Radenbaugh, A.J.; Kim, H.J.; Emerson, B.M.; Pourmand, N. Single-cell analyses of transcriptional heterogeneity during drug tolerance transition in cancer cells by RNA sequencing. Proc. Natl. Acad. Sci. USA 2014, 111, E4726–E4735.
48. Gillies, R.J.; Verduzco, D.; Gatenby, R.A. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nat. Rev. Cancer 2012, 12, 487–493.
49. Garrido, F.; Cabrera, T.; Concha, A.; Glew, S.; Ruiz-Cabello, F.; Stern, P.L. Natural history of HLA expression during tumour development. Immunol. Today 1993, 14, 491–499.
50. Garrido, F.; Ruiz-Cabello, F.; Cabrera, T.; Pérez-Villar, J.J.; López-Botet, M.; Duggan-Keen, M.; Stern, P.L. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today 1997, 18, 89–95.
51. Garrido, F.; Cabrera, T.; Aptsiauri, N. “Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapy. Int. J. Cancer 2010, 127, 249–256.
52. Bernal, M.; Concha, A.; Sáenz-López, P.; Rodríguez, A.I.; Cabrera, T.; Garrido, F.; Ruiz-Cabello, F. Leukocyte infiltrate in gastrointestinal adenocarcinomas is strongly associated with tumor microsatellite instability but not with tumor immunogenicity. Cancer Immunol. Immunother. 2011, 60, 869–882.
53. Bernal, M.; García-Alcalde, F.; Concha, A.; Cano, C.; Blanco, A.; Garrido, F.; Ruiz-Cabello, F. Genome-wide differential genetic profiling characterizes colorectal cancers with genetic instability and specific routes to HLA class I loss and immune escape. Cancer Immunol. Immunother. 2012, 61, 803–816.
54. Galon, J.; Mlecnik, B.; Bindea, G.; Angell, H.K.; Berger, A.; Lagorce, C.; Lugli, A.; Zlobec, I.; Hartmann, A.; Bifulco, C., et al. Towards the introduction of the “Immunoscore” in the classification of malignant tumours. J. Pathol. 2014, 232, 199–209.
55. Pagès, F.; Kirilovsky, A.; Mlecnik, B.; Asslaber, M.; Tosolini, M.; Bindea, G.; Lagorce, C.; Wind, P.; Marliot, F.; Bruneval, P., et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J. Clin. Oncol. 2009, 27, 5944–5951.
56. Mlecnik, B.; Tosolini, M.; Kirilovsky, A.; Berger, A.; Bindea, G.; Meatchi, T.; Bruneval, P.; Trajanoski, Z.; Fridman, W.H.; Pagès, F., et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J. Clin. Oncol. 2011, 29, 610–618.
57. Broussard, E.K.; Disis, M.L. TNM staging in colorectal cancer: T is for T Cell and M is for memory. J. Clin. Oncol. 2011, 29, 601–603.
58. Van Zijl, F.; Krupitza, G.; Mikulits, W. Initial steps of metastasis: Cell invasion and endothelial transmigration. Mutat. Res.-Rev. Mutat. Res. 2011, 728, 23–34.
59. Yu, M.; Bardia, A.; Wittner, B.S.; Stott, S.L.; Smas, M.E.; Ting, D.T.; Isakoff, S.J.; Ciciliano, J.C.; Wells, M.N.; Shah, A.M., et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013, 339, 580–584.
60. Tsai, J.H.; Yang, J. Epithelial-mesenchymal plasticity in carcinoma metastasis. Genes Dev. 2013, 27, 2192–2206.
61. Kalikaki, A.; Politaki, H.; Souglakos, J.; Apostolaki, S.; Papadimitraki, E.; Georgoulia, N.; Tzardi, M.; Mavroudis, D.; Georgoulias, V.; Voutsina, A. KRAS genotypic changes of circulating tumor cells during treatment of patients with metastatic colorectal cancer. PLoS ONE 2014, 9, e104902.
62. Bettegowda, C.; Sausen, M.; Leary, R.J.; Kinde, I.; Wang, Y.; Agrawal, N.; Bartlett, B.R.; Wang, H.; Luber, B.; Alani, R.M., et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 2014, 6, 224ra24.
63. Diaz, L.A.; Williams, R.T.; Wu, J.; Kinde, I.; Hecht, J.R.; Berlin, J.; Allen, B.; Bozic, I.; Reiter, J.G.; Nowak, M.A., et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012, 486, 537–540.
64. Misale, S.; Yaeger, R.; Hobor, S.; Scala, E.; Janakiraman, M.; Liska, D.; Valtorta, E.; Schiavo, R.; Buscarino, M.; Siravegna, G., et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012, 486, 532–576.
65. Misale, S.; Arena, S.; Lamba, S.; Siravegna, G.; Lallo, A.; Hobor, S.; Russo, M.; Buscarino, M.; Lazzari, L.; Sartore-Bianchi, A., et al. Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer. Sci. Transl. Med. 2014, 6, 224ra26.
66. Molinari, F.; Felicioni, L.; Buscarino, M.; de Dosso, S.; Buttitta, F.; Malatesta, S.; Movilia, A.; Luoni, M.; Boldorini, R.; Alabiso, O., et al. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin. Cancer Res. 2011, 17, 4901–4914.
67. Tougeron, D.; Lecomte, T.; Pagès, J.C.; Villalva, C.; Collin, C.; Ferru, A.; Tourani, J.M.; Silvain, C.; Levillain, P.; Karayan-tapon, L. Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer. Ann. Oncol. 2013, 24, 1267–1273.
68. Yu, S.; Xiao, X.; Lu, J.; Qian, X.; Liu, B.; Feng, J. Colorectal cancer patients with low abundance of KRAS mutation may benefit from EGFR antibody therapy. PLoS ONE 2013, 8, e68022.
69. Schwarzenbach, H.; Nishida, N.; Calin, G.A.; Pantel, K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat. Rev. Clin. Oncol. 2014, 11, 145–156.
70. Hanash, S.M.; Pitteri, S.J.; Faca, V.M. Mining the plasma proteome for cancer biomarkers. Nature 2008, 452, 571–579.
71. Wang, K.; Huang, C.; Nice, E.C. Proteomics, genomics and transcriptomics: Their emerging roles in the discovery and validation of colorectal cancer biomarkers. Expert Rev. Proteomics 2014, 11, 179–205.
72. Jain, M.; Nilsson, R.; Sharma, S.; Madhusudhan, N.; Kitami, T.; Souza, A.L.; Kafri, R.; Kirschner, M.W.; Clish, C.B.; Mootha, V.K. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 2012, 336, 1040–1044.
73. Loo, J.M.; Scherl, A.; Nguyen, A.; Man, F.Y.; Weinberg, E.; Zeng, Z.; Saltz, L.; Paty, P.B.; Tavazoie, S.F. Extracellular metabolic energetics can promote cancer progression. Cell 2015, 160, 393–406.
74. Navin, N.; Kendall, J.; Troge, J.; Andrews, P.; Rodgers, L.; McIndoo, J.; Cook, K.; Stepansky, A.; Levy, D.; Esposito, D., et al. Tumour evolution inferred by single-cell sequencing. Nature 2011, 472, 90–94.
75. Yachida, S.; Jones, S.; Bozic, I.; Antal, T.; Leary, R.; Fu, B.; Kamiyama, M.; Hruban, R.H.; Eshleman, J.R.; Nowak, M.A., et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010, 467, 1114–1117.
76. Artale, S.; Sartore-Bianchi, A.; Veronese, S.M.; Gambi, V.; Sarnataro, C.S.; Gambacorta, M.; Lauricella, C.; Siena, S. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J. Clin. Oncol. 2008, 26, 4217–4219.
77. Knijn, N.; Mekenkamp, L.J.M.; Klomp, M.; Vink-Börger, M.E.; Tol, J.; Teerenstra, S.; Meijer, J.W.R.; Tebar, M.; Riemersma, S.; van Krieken, J.H.J.M., et al. KRAS mutation analysis: A comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br. J. Cancer 2011, 104, 1020–1026.
78. Mao, C.; Wu, X.; Yang, Z.; Threapleton, D.E.; Yuan, J.; Yu, Y.; Tang, J. Concordant analysis of KRAS, BRAF, PIK3CA mutations, and PTEN expression between primary colorectal cancer and matched metastases. Sci. Rep. 2015, 5, doi:10.1038/srep08065.
79. Brannon, A.R.; Vakiani, E.; Sylvester, B.E.; Scott, S.N.; McDermott, G.; Shah, R.H.; Kania, K.; Viale, A.; Oschwald, D.M.; Vacic, V., et al. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol. 2014, 15, 454.
80. Vakiani, E.; Janakiraman, M.; Shen, R.; Sinha, R.; Zeng, Z.; Shia, J.; Cercek, A.; Kemeny, N.; D’Angelica, M.; Viale, A., et al. Comparative genomic analysis of primary versus metastatic colorectal carcinomas. J. Clin. Oncol. 2012, 30, 2956–2962.
81. Vignot, S.; Lefebvre, C.; Frampton, G.M.; Meurice, G.; Yelensky, R.; Palmer, G.; Capron, F.; Lazar, V.; Hannoun, L.; Miller, V.A., et al. Comparative analysis of primary tumour and matched metastases in colorectal cancer patients: Evaluation of concordance between genomic and transcriptional profiles. Eur. J. Cancer 2015, 51, 791–799.
82. Jesinghaus, M.; Wolf, T.; Pfarr, N.; Muckenhuber, A.; Ahadova, A.; Warth, A.; Goeppert, B.; Sers, C.; Kloor, M.; Endris, V., et al. Distinctive spatiotemporal stability of somatic mutations in metastasized microsatellite-stable colorectal cancer. Am. J. Surg. Pathol. 2015, in press.
83. Turtoi, A.; Blomme, A.; Debois, D.; Somja, J.; Delvaux, D.; Patsos, G.; di Valentin, E.; Peulen, O.; Mutijima, E.N.; de Pauw, E., et al. Organized proteomic heterogeneity in colorectal cancer liver metastases and implications for therapies. Hepatology 2014, 59, 924–934.
84. Paterson, E.L.; Kazenwadel, J.; Bert, A.G.; Khew-Goodall, Y.; Ruszkiewicz, A.; Goodall, G.J. Down-regulation of the miRNA-200 family at the invasive front of colorectal cancers with degraded basement membrane indicates EMT is involved in cancer progression. Neoplasia 2013, 15, 180–191.
85. Siena, S.; Sartore-Bianchi, A.; di Nicolantonio, F.; Balfour, J.; Bardelli, A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J. Natl. Cancer Inst. 2009, 101, 1308–1324.
86. De Roock, W.; de Vriendt, V.; Normanno, N.; Ciardiello, F.; Tejpar, S. KRAS, BRAF, PIK3CA, and PTEN mutations: Implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol. 2011, 12, 594–603.
87. Mao, C.; Liao, R.-Y.; Qiu, L.-X.; Wang, X.-W.; Ding, H.; Chen, Q. BRAF V600E mutation and resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer: A meta-analysis. Mol. Biol. Rep. 2011, 38, 2219–2223.
88. Díaz-Rubio, E.; Gómez-España, A.; Massutí, B.; Sastre, J.; Reboredo, M.; Manzano, J.L.; Rivera, F.; Safont, M.J.; Montagut, C.; González, E., et al. Role of kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: A TTD group cooperative study. PLoS ONE 2012, 7, e47345.
89. Douillard, J.-Y.; Oliner, K.S.; Siena, S.; Tabernero, J.; Burkes, R.; Barugel, M.; Humblet, Y.; Bodoky, G.; Cunningham, D.; Jassem, J., et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med. 2013, 369, 1023–1034.
90. Van Cutsem, E.; Lenz, H.-J.; Kohne, C.-H.; Heinemann, V.; Tejpar, S.; Melezinek, I.; Beier, F.; Stroh, C.; Rougier, P.; van Krieken, J.H., et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J. Clin. Oncol. 2015, 33, 692–700.
91. Bozic, I.; Nowak, M.A. Timing and heterogeneity of mutations associated with drug resistance in metastatic cancers. Proc. Natl. Acad. Sci. USA 2014, 111, 15964–15968.
92. Montagut, C.; Dalmases, A.; Bellosillo, B.; Crespo, M.; Pairet, S.; Iglesias, M.; Salido, M.; Gallen, M.; Marsters, S.; Tsai, S.P., et al. Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer. Nat. Med. 2012, 18, 1445–1445.
93. Jeffers, M.; van Cutsem, E.; Sobrero, A.F.; Siena, S.; Falcone, A.; Ychou, M.; Humblet, Y.; Bouche, O.; Mineur, L.; Barone, C., et al. Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib. J. Clin. Oncol. 2013, 31, 381.
94. Bedard, P.L.; Hansen, A.R.; Ratain, M.J.; Siu, L.L. Tumour heterogeneity in the clinic. Nature 2013, 501, 355–364.
95. Bokemeyer, C.; van Cutsem, E.; Rougier, P.; Ciardiello, F.; Heeger, S.; Schlichting, M.; Celik, I.; Köhne, C.-H. Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur. J. Cancer 2012, 48, 1466–1475.
96. Ciardiello, F.; Normanno, N.; Maiello, E.; Martinelli, E.; Troiani, T.; Pisconti, S.; Giuliani, F.; Barone, C.; Cartenì, G.; Rachiglio, A.M., et al. Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next generation sequencing: Findings from the CAPRI-GOIM trial. Ann. Oncol. 2014, 25, 1756–1761.
97. Venderbosch, S.; Nagtegaal, I.D.; Maughan, T.S.; Smith, C.G.; Cheadle, J.P.; Fisher, D.; Kaplan, R.; Quirke, P.; Seymour, M.T.; Richman, S., et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: A pooled analysis of the CAIRO, CAIRO2, COIN and FOCUS studies. Clin. Cancer Res. 2014, 20, 5322–5331.
98. Laurent-Puig, P.; Pekin, D.; Normand, C.; K Kotsopoulos, S.; Nizard, P.; Perez Toralla, K.; Rowell, R.; Olson, J.; Srinivasan, P.; Le Corre, D., et al. Clinical relevance of KRAS-mutated sub-clones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy. Clin. Cancer Res. 2015, 21, 1087–1097.
99. Sorich, M.J.; Wiese, M.D.; Rowland, A.; Kichenadasse, G.; McKinnon, R.A.; Karapetis, C.S. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: A meta-analysis of randomized controlled trials. Ann. Oncol. 2014, 26, 1–27.
100. Roth, A.D.; Tejpar, S.; Delorenzi, M.; Yan, P.; Fiocca, R.; Klingbiel, D.; Dietrich, D.; Biesmans, B.; Bodoky, G.; Barone, C., et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J. Clin. Oncol. 2010, 28, 466–474.
101. Ogino, S.; Shima, K.; Meyerhardt, J.A.; McCleary, N.J.; Ng, K.; Hollis, D.; Saltz, L.B.; Mayer, R.J.; Schaefer, P.; Whittom, R., et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: Results from intergroup trial CALGB 89803. Clin Cancer Res 2012, 18, 890–900.
102. Richman, S.D.; Seymour, M.T.; Chambers, P.; Elliott, F.; Daly, C.L.; Meade, A.M.; Taylor, G.; Barrett, J.H.; Quirke, P. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: Results from the MRC FOCUS trial. J. Clin. Oncol. 2009, 27, 5931–5937.
103. Lochhead, P.; Kuchiba, A.; Imamura, Y.; Liao, X.; Yamauchi, M.; Nishihara, R.; Qian, Z.R.; Morikawa, T.; Shen, J.; Meyerhardt, J.A., et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J. Natl. Cancer Inst. 2013, 105, 1151–1156.
104. Popat, S.; Hubner, R.; Houlston, R.S. Systematic review of microsatellite instability and colorectal cancer prognosis. J. Clin. Oncol. 2005, 23, 609–618.
105. Hutchins, G.; Southward, K.; Handley, K.; Magill, L.; Beaumont, C.; Stahlschmidt, J.; Richman, S.; Chambers, P.; Seymour, M.; Kerr, D., et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J. Clin. Oncol. 2011, 29, 1261–1270.
106. Des Guetz, G.; Schischmanoff, O.; Nicolas, P.; Perret, G.-Y.; Morere, J.-F.; Uzzan, B. Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur. J. Cancer 2009, 45, 1890–1896.
107. Sargent, D.J.; Marsoni, S.; Monges, G.; Thibodeau, S.N.; Labianca, R.; Hamilton, S.R.; French, A.J.; Kabat, B.; Foster, N.R.; Torri, V., et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J. Clin. Oncol. 2010, 28, 3219–3226.
108. Sinicrope, F.A.; Foster, N.R.; Thibodeau, S.N.; Marsoni, S.; Monges, G.; Labianca, R.; Kim, G.P.; Yothers, G.; Allegra, C.; Moore, M.J., et al. DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J. Natl. Cancer Inst. 2011, 103, 863–875.
109. Koopman, M.; Kortman, G.A.M.; Mekenkamp, L.; Ligtenberg, M.J.L.; Hoogerbrugge, N.; Antonini, N.F.; Punt, C.J.A.; van Krieken, J.H.J.M. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br. J. Cancer 2009, 100, 266–273.
110. Bertagnolli, M.M.; Niedzwiecki, D.; Compton, C.C.; Hahn, H.P.; Hall, M.; Damas, B.; Jewell, S.D.; Mayer, R.J.; Goldberg, R.M.; Saltz, L.B., et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J. Clin. Oncol. 2009, 27, 1814–1821.
111. Ribic, C.M.; Sargent, D.J.; Moore, M.J.; Thibodeau, S.N.; French, A.J.; Goldberg, R.M.; Hamilton, S.R.; Laurent-Puig, P.; Gryfe, R.; Shepherd, L.E., et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med. 2003, 349, 247–257.
112. Mao, C.; Yang, Z.Y.; Hu, X.F.; Chen, Q.; Tang, J.L. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis. Ann. Oncol. 2012, 23, 1518–1525.
113. Kishiki, T.; Ohnishi, H.; Masaki, T.; Ohtsuka, K.; Ohkura, Y.; Furuse, J.; Watanabe, T.; Sugiyama, M. Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS. Cancer Chemother. Pharmacol. 2014, 73, 749–757.
114. Shoji, H.; Yamada, Y.; Taniguchi, H.; Nagashima, K.; Okita, N.; Takashima, A.; Honma, Y.; Iwasa, S.; Kato, K.; Hamaguchi, T., et al. Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection. Cancer Sci 2014, 105, 1002–1007.
115. Jiang, Z.; Li, C.; Li, F.; Wang, X. EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: A systematic review and meta analysis. PLoS ONE 2013, 8, e56205.
116. Kristensen, V.N.; Lingjærde, O.C.; Russnes, H.G.; Vollan, H.K.M.; Frigessi, A.; Børresen-Dale, A.-L. Principles and methods of integrative genomic analyses in cancer. Nat. Rev. Cancer 2014, 14, 299–313.
117. Werner, H.M.J.; Mills, G.B.; Ram, P.T. Cancer systems biology: A peek into the future of patient care? Nat. Rev. Clin. Oncol. 2014, 11, 167–176.
118. Samur, M.K.; Yan, Z.; Wang, X.; Cao, Q.; Munshi, N.C.; Li, C.; Shah, P.K. canEvolve: A web portal for integrative oncogenomics. PLoS ONE 2013, 8, e56228.
119. Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E., et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 2013, 6, doi:10.1126/scisignal.2004088.